BACKGROUND: Targeted sequencing of patients with epidemiologically low-risk (ELR) head and neck squamous cell carcinoma (HNSCC) could help identify novel drivers or lost suppressors leading to precision medicine protocols and improved survival rates. METHODS: A patient with ELR-HNSCC was selected for targeted sequencing. We then assessed next generation sequencing cohorts from the Oncomine Powertool Database, which contains pan-cancer data from The Cancer Genome Atlas (TCGA). RESULTS: Targeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor. Patients with HNSCC from TCGA data demonstrated fibroblast growth factor (FGF) family mutations, rearrangements, or amplifications in over 35% of HNSCC cases, with a statistically significant higher frequency in African American populations. FGF alterations were unique from activating phosphatidylinositol 3-kinase (PIK3CA) mutations. CONCLUSION: Together, these data suggest that FGF signaling may be critical for a subset of patients with HNSCC independent of other known pathways and provides rationale for leveraging patients with ELR-HNSCC to define molecular subsets of high-risk HNSCC.
BACKGROUND: Targeted sequencing of patients with epidemiologically low-risk (ELR) head and neck squamous cell carcinoma (HNSCC) could help identify novel drivers or lost suppressors leading to precision medicine protocols and improved survival rates. METHODS: A patient with ELR-HNSCC was selected for targeted sequencing. We then assessed next generation sequencing cohorts from the Oncomine Powertool Database, which contains pan-cancer data from The Cancer Genome Atlas (TCGA). RESULTS: Targeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor. Patients with HNSCC from TCGA data demonstrated fibroblast growth factor (FGF) family mutations, rearrangements, or amplifications in over 35% of HNSCC cases, with a statistically significant higher frequency in African American populations. FGF alterations were unique from activating phosphatidylinositol 3-kinase (PIK3CA) mutations. CONCLUSION: Together, these data suggest that FGF signaling may be critical for a subset of patients with HNSCC independent of other known pathways and provides rationale for leveraging patients with ELR-HNSCC to define molecular subsets of high-risk HNSCC.
Authors: Fabrice André; Thomas Bachelot; Mario Campone; Florence Dalenc; Jose M Perez-Garcia; Sara A Hurvitz; Nicholas Turner; Hope Rugo; John W Smith; Stephanie Deudon; Michael Shi; Yong Zhang; Andrea Kay; Diana Graus Porta; Alejandro Yovine; José Baselga Journal: Clin Cancer Res Date: 2013-05-08 Impact factor: 12.531
Authors: Joshua I Warrick; Daniel H Hovelson; Anmol Amin; Chia-Jen Liu; Andi K Cani; Andrew S McDaniel; Venkata Yadati; Michael J Quist; Alon Z Weizer; J Chad Brenner; Felix Y Feng; Rohit Mehra; Catherine S Grasso; Scott A Tomlins Journal: Virchows Arch Date: 2014-12-11 Impact factor: 4.064
Authors: F Courjal; M Cuny; J Simony-Lafontaine; G Louason; P Speiser; R Zeillinger; C Rodriguez; C Theillet Journal: Cancer Res Date: 1997-10-01 Impact factor: 12.701
Authors: Curtis R Pickering; Jiexin Zhang; Suk Young Yoo; Linnea Bengtsson; Shhyam Moorthy; David M Neskey; Mei Zhao; Marcus V Ortega Alves; Kyle Chang; Jennifer Drummond; Elsa Cortez; Tong-Xin Xie; Di Zhang; Woonbok Chung; Jean-Pierre J Issa; Patrick A Zweidler-McKay; Xifeng Wu; Adel K El-Naggar; John N Weinstein; Jing Wang; Donna M Muzny; Richard A Gibbs; David A Wheeler; Jeffrey N Myers; Mitchell J Frederick Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: Johannes Schödel; Chiara Bardella; Lina K Sciesielski; Jill M Brown; Chris W Pugh; Veronica Buckle; Ian P Tomlinson; Peter J Ratcliffe; David R Mole Journal: Nat Genet Date: 2012-03-11 Impact factor: 38.330
Authors: Amit Dutt; Alex H Ramos; Peter S Hammerman; Craig Mermel; Jeonghee Cho; Tanaz Sharifnia; Ajit Chande; Kumiko Elisa Tanaka; Nicolas Stransky; Heidi Greulich; Nathanael S Gray; Matthew Meyerson Journal: PLoS One Date: 2011-06-07 Impact factor: 3.240
Authors: Joshua Smith; Aditi Kulkarni; Andrew C Birkeland; Jonathan B McHugh; J Chad Brenner Journal: Otolaryngol Head Neck Surg Date: 2018-05-08 Impact factor: 3.497
Authors: Paul L Swiecicki; Julia R Brennan; Michelle Mierzwa; Matthew E Spector; J Chad Brenner Journal: Laryngoscope Date: 2018-12-20 Impact factor: 3.325
Authors: Megan L Ludwig; Aditi Kulkarni; Andrew C Birkeland; Nicole L Michmerhuizen; Susan K Foltin; Jacqueline E Mann; Rebecca C Hoesli; Samantha N Devenport; Brittany M Jewell; Andrew G Shuman; Matthew E Spector; Thomas E Carey; Hui Jiang; J Chad Brenner Journal: Oral Oncol Date: 2018-11-08 Impact factor: 5.337
Authors: Joshua D Smith; Andrew C Birkeland; Andrew J Rosko; Rebecca C Hoesli; Susan K Foltin; Paul Swiecicki; Michelle Mierzwa; Steven B Chinn; Andrew G Shuman; Kelly M Malloy; Keith A Casper; Scott A McLean; Gregory T Wolf; Carol R Bradford; Mark E Prince; John Chad Brenner; Matthew E Spector Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: Andrew C Birkeland; Sarah J Burgin; Megan Yanik; Megan V Scott; Carol R Bradford; Jonathan B McHugh; Scott A McLean; Stephen E Sullivan; Jacques E Nor; Erin L McKean; J Chad Brenner Journal: J Neurol Surg B Skull Base Date: 2017-03-27
Authors: Andrew C Birkeland; Susan K Foltin; Nicole L Michmerhuizen; Rebecca C Hoesli; Andrew J Rosko; Serena Byrd; Megan Yanik; Jacques E Nor; Carol R Bradford; Mark E Prince; Thomas E Carey; Jonathan B McHugh; Matthew E Spector; J Chad Brenner Journal: Oral Oncol Date: 2017-03-10 Impact factor: 5.337